Bexotegrast 治疗原发性硬化性胆管炎的 II 期 INTEGRIS-PSC 试验
这项 II 期双盲、剂量探索研究将 117 例原发性硬化性胆管炎(PSC)合并肝纤维化参与者按 3:1 随机分配接受每日一次口服 bexotegrast(40、80、160、320 mg)或安慰剂,主要终点为治疗中出现的不良事件(TEAE)发生率。Bexotegrast 耐受性良好,合并用药组与安慰剂组 TEAE 发生率相似(72.7% 与 70.0%),未观察到与研究药物相关的严重 TEAE;第 12 周时 ELF 评分、PRO-C3 和 MRI 评估显示 bexotegrast 组药效学进展在数值上少于安慰剂组。
要点
- Bexotegrast 在 PSC 合并肝纤维化参与者中耐受性良好,TEAE 多为轻至中度。
- 合并 bexotegrast 组与安慰剂组 TEAE 发生率分别为 72.7% 和 70.0%。
- 第 12 周 ELF 评分、PRO-C3 和 MRI 评估显示 bexotegrast 组药效学进展数值上少于安慰剂。
核心结论
- Bexotegrast 在 PSC 合并肝纤维化参与者中长达 40 周耐受性良好,并与探索性药效学标志物进展数值上减少相关。
研究设计与样本
- II 期双盲、剂量探索研究,117 例 PSC 参与者按 3:1 随机接受每日一次口服 bexotegrast 或安慰剂。
- 分三部分:第 1 部分 40 mg 或安慰剂 12 周;第 2 部分 80 mg、160 mg 或安慰剂 12 周;第 3 部分 320 mg 或安慰剂最长 40 周。
- 主要终点为治疗中出现的不良事件(TEAE)发生率。
主要发现
- 共 117 例参与者接受 bexotegrast(40 mg n=22;80 mg n=21;160 mg n=21;320 mg n=27)或安慰剂(n=30)。
- 合并 bexotegrast 组与安慰剂组 TEAE 发生率分别为 72.7% 和 70.0%。
- TEAE 为轻至中度,未观察到与研究药物相关的严重 TEAE。
- 第 12 周时 bexotegrast 组 ELF 评分、PRO-C3 和 MRI 评估的药效学进展在数值上少于安慰剂组。
- 第 24 周药效学结果较第 12 周变化有限,但 MRI 参数继续改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Transforming growth factor-β signaling activated by αvβ6 and αvβ1 integrins drives liver fibrosis in primary sclerosing cholangitis (PSC). The aim of this study was to investigate the safety and exploratory pharmacodynamics of bexotegrast (PLN-74809), an oral, once-daily inhibitor of αvβ6 and αvβ1 integrins, in participants with PSC and liver fibrosis. METHODS: In this phase II, double-blind, dose-ranging study, 117 participants with PSC were randomized 3:1 to receive once-daily oral bexotegrast or placebo in three cohorts: 40 mg or placebo for 12 weeks (part 1); 80 mg, 160 mg, or placebo for 12 weeks (part 2); and 320 mg or placebo for up to 40 weeks (part 3). The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs). Exploratory pharmacodynamic endpoints included changes in alkaline phosphatase values, enhanced liver fibrosis (ELF) scores, neoepitope-specific N-terminal pro-peptide of type III collagen (PRO-C3) levels, liver stiffness measurements, gadoxetate-enhanced MRI measures, and the Itch Numeric Rating Scale. RESULTS: A total of 117 participants received bexotegrast (40 mg [n = 22], 80 mg [n = 21], 160 mg [n = 21], 320 mg [n = 27]) or placebo (n = 30). Bexotegrast was well tolerated, with similar rates of TEAEs in the pooled bexotegrast and placebo groups (72.7% and 70.0%). TEAEs were mild to moderate, and no serious TEAEs related to study drug were observed. Numerically less pharmacodynamic progression was observed with bexotegrast in ELF score, PRO-C3, and MRI assessments at Week 12 compared with placebo. Pharmacodynamic results at Week 24 showed limited change from Week 12 except in MRI parameters which continued to improve. CONCLUSIONS: Bexotegrast was well tolerated for up to 40 weeks in participants with PSC and liver fibrosis and was associated with numerically less progression in exploratory pharmacodynamic markers. IMPACT AND IMPLICATIONS: Primary sclerosing cholangitis (PSC) is a rare cholestatic disease of unknown etiology. Currently, there is an unmet medical need for safe and effective therapies capable of halting or reversing progression of PSC. In this phase II study in participants with PSC and suspected liver fibrosis, bexotegrast, an oral, once-daily, dual selective inhibitor of αvβ6 and αvβ1 integrins, had a favorable safety and tolerability profile. This study supports targeting integrin-mediated transforming growth factor-β activation as a potential therapeutic approach for PSC. TRIAL REGISTRATION NUMBER: NCT04480840.
引用
- Hirschfield GM, Kowdley KV, Trivedi PJ, et al. Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1 integrin inhibitor, in primary sclerosing cholangitis. J Hepatol. 2025. PMID: 41016442. doi:10.1016/j.jhep.2025.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。